Copyright
©The Author(s) 2022.
World J Nephrol. May 25, 2022; 11(3): 86-95
Published online May 25, 2022. doi: 10.5527/wjn.v11.i3.86
Published online May 25, 2022. doi: 10.5527/wjn.v11.i3.86
Stage | Description | GFR, mL/min/1.73 m2 |
- | At increased risk | ≥ 60 |
1 | Kidney damage with normal or increased GFR | ≥ 90 |
2 | Kidney damage with mild decreased GFR | 60-89 |
3 | Moderately decreased GFR | 30-59 |
4 | Severely decreased GFR | 15-29 |
5 | Kidney Failure | < 15 (or dialysis) |
BP phenotype | Description1 | All-cause mortality hazard ratio (95%CI) |
Normotension | Normal clinic BP, normal 24-h ABPM | Reference |
White-coat hypertension | High clinic BP, normal 24-h ABPM | 1.79 (1.38–2.32) |
Sustained hypertension | High clinic BP, high 24-h ABPM | 1.80 (1.41–2.31) |
Masked hypertension | Normal clinic BP, high 24-h ABPM | 2.83 (2.12–3.79) |
Trial | Objective | Design/primary endpoints | Drug/procedures used | Main outcomes | Benefits on renal parameters |
ALLHAT | To determine whether treatment with a CCB or an ACE inhibitor lowers the incidence of CHD or other CVD events vs treatment with a diuretic | A total of 33357 participants aged 55 yr or older with HTN and at least 1 other CHD risk factor from 623 North American centers were enrolled. Primary Endpoints: Combined fatal CHD or nonfatal MI analyzed by intent-to-treat | Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); ALM, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 yr | In patients with HTN, chlorthalidone, ALM, and lisinopril performed similarly in regard to fatal CAD and nonfatal MI | Post hoc analysis of the trial revealed that in hypertensive patients with reduced GFR, both ALM and lisinopril performed similarly in reducing the rate of development of ESRD |
ACCOMPLISH | To evaluate the effect of ALM vs hydrochlorothiazide in patients with HTN who are at high risk CVD | Multi-centered, double-blind, randomized, controlled trial with 548 centers in the US and Europe. 11506 subjects were enrolled who received Benazepril/ALM (n = 5744) or Benazepril/HCTZ (n = 5762). Primary Endpoint: CV mortality, nonfatal MI, nonfatal CVA, UA, resuscitation after cardiac arrest, or coronary revascularization | Subjects received benazepril/ALM 20 mg/5 mg or benazepril/HCTZ 20 mg/12.5 mg daily. Benazepril component was increased to 40 mg after 1 mo.Increase of ALM to 10 mg or HCTZ to 25 mg to reach target BP < 140/90 or < 130/80 | Among patients with HTN at high risk for CV complications, benazepril/ALM decreases the rate of CV events as compared to benazepril/HCTZ | Initial antihypertensive treatment with benazepril and ALM demonstrates a superior ability in reducing the progression of nephropathy |
SAKURA | To clarify whether the L-/N-type CCB cilnidipine is more renoprotective than the L-type CCB ALM in patients with early-stage diabetic nephropathy | Prospective, multicenter, open-labeled, randomized trial in 77 clinics and hospitals in Japan, to probe the anti-albuminuric effects of cilnidipine and ALM in 367 RAAS inhibitor-treated patients with HTN (BP: 130-180/80-110 mmHg), type 2 diabetes, and microalbuminuria (UACR: 30-300 mg/g). Primary Endpoint: Change in the urinary albumin/Cr ratio after a 1-yr treatment | Study subjects were randomly allocated in two groups and treated with cilnidipine (started at 10 mg/d, then adjusted to 5-20 mg/d) or ALM (started at 5 mg/d, then adjusted to 2.5-10 mg/d). The target BP was < 130/80 mm Hg | Cilnidipine did not offer greater renoprotection than ALM in RAS inhibitor treated HTN patients with type 2 diabetes and microalbuminuria | In hypertensive patients with proteinuria, L/N- and L/T-type CCBs as add-on therapy to an ACEI or an ARB reduce albuminuria and proteinuria and improve kidney function compared with the use of an ACEI or ARB alone or in combination with other antihypertensive agents |
ASCOT-BPLA | To evaluate whether treatment with a newer anti-hypertensive regimen of CCB with or without an ACE inhibitor is more effective than an older regimen of β-blocker with or without a diuretic, and whether it reduces CHD events in hypertensive patients with relatively low cholesterol levels | A total of 19257 patients with SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg (untreated) or SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg (treated); total cholesterol ≤ 6.5 mmol/L (250 mg/dL) and triglycerides ≤ 4.5 mmol/L (400 mg/dL); age 40-79 yr; ≥ 3 CVD risk factors; and no history of CHD were enrolled Primary Endpoints: Nonfatal MI and fatal CHD | Patients were randomized open-label to one of the two anti-hypertensive treatments: ALM 5 mg (n = 9639) or atenolol 50 mg (n = 9618). In order to achieve target BP goals of < 140/90 mm Hg, study drug doses were increased, and second-line drugs were added (perindopril 4 mg for the ALM group and bendroflumethiazide 1.25 mg for the atenolol group) | ALM-based regimen is superior to an atenolol-based regimen in regard to demonstrating a greater reduction in BP variability and prevention of major CV events in patients with HTN | ALM based arm demonstrated a significant reduction in new onset diabetes mellitus, development of peripheral arterial disease and renal impairment |
- Citation: Abraham G, Almeida A, Gaurav K, Khan MY, Patted UR, Kumaresan M. Reno protective role of amlodipine in patients with hypertensive chronic kidney disease. World J Nephrol 2022; 11(3): 86-95
- URL: https://www.wjgnet.com/2220-6124/full/v11/i3/86.htm
- DOI: https://dx.doi.org/10.5527/wjn.v11.i3.86